The gastric pentadecapeptide
BPC 157, which was shown to be safe as an antiulcer
peptide in trials for
inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and
fistula in rat. Therefore, we studied for 4 weeks rats with escalating
short bowel syndrome and progressive
weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in
drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice). Postoperatively, features of increasingly exhausted presentation were:
weight loss appearing immediately regardless of villus height, twofold increase in crypt depth and fourfold increase in muscle thickness within the first week, jejunal and ileal overdilation, and disturbed jejunum/ileum relation. In contrast, constant
weight gain above preoperative values was observed immediately with
BPC 157 therapy, both perorally and parenterally, and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days. Moreover, rats treated with pentadecapeptide
BPC 157 showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength. In conclusion, pentadecapeptide
BPC 157 could be helpful to cure
short bowel syndrome.